MSACL 2017 US Abstract

Improved Diagnosis and Treatment of Patients Through Accurate and Standardized Estradiol Tests

Julianne Cook Botelho (Presenter)
Centers for Disease Control and Prevention

Short Abstract

Accurate and reliable estradiol (E2) measurements are vital to monitor breast cancer patients on aromatase inhibitors and IVF patients on ovarian stimulation therapy as well as to assess risk for estrogen secreting tumors and factures. CDC is ensuring accurate E2 measurements by maintaining a highly accurate and precise reference method as well as providing serum reference materials through the Hormone Standardization Program (HoSt). E2 requires a method with high sensitivity to address the need for low pg/mL measurements and a method with high specificity, free from potential interferences. CDC is working to ensure that laboratory results in research and patient care are accurate, reliable, and meet the needs defined by stakeholders such as The Partnership for Accurate Testing of Hormones (PATH).

Long Abstract

Accurate and reliable estradiol (E2) measurements are vital to monitor breast cancer patients on aromatase inhibitor therapy and IVF patients on ovarian stimulation therapy as well as to assess patientís risk for infertility, estrogen secreting tumors, and factures. CDC is ensuring accurate E2 measurements by maintaining a highly accurate and precise reference measurement procedure (RMP) as well as providing single-donor serum reference materials to assess method performance through its Hormone Standardization Program (HoSt). E2 measurements require a method with high sensitivity to address the need for low pg/mL measurements in postmenopausal women as well as and a method with high specificity to ensure measurements are accurate and free from potential interferences from structural analogs and other steroid hormones. The decision to use derivatization as well as the selection of chromatography is important to acquire accurate results with LC-MS/MS. CDC is working to ensure that laboratory results in research and patient care are accurate, reliable, and continue to meet the needs defined by stakeholders such as The Partnership for Accurate Testing of Hormones (PATH) to address this vital need.


References & Acknowledgements:


Financial Disclosure

DescriptionY/NSource
Grantsno
Salaryno
Board Memberno
Stockno
Expensesno

IP Royalty: no

Planning to mention or discuss specific products or technology of the company(ies) listed above:

no